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Dear Colleague,
The year of 2013 in cardiology has been
eventful with significant advances described in
many fields including cardiac pharmacology,
coronary artery intervention, percutaneous
aortic valve implantation, heart failure, and
electrophysiology. Perhaps one of the most
rapidly expanding areas is that of renal
denervation therapy (RDT) for treatment of
resistant hypertension.
Catheter-based radiofrequency ablation of
the efferent and afferent sympathetic nerves
which lie within and just beyond the adventitia
of the renal arteries has been shown to be a
highly effective treatment for resistant
hypertension (Fig. 1). Potential beneficial
mechanisms include reduction in peripheral
resistance, reduced renin release, favorable
changes in water and salt handling, and
reduction in whole-body sympathetic-nerve
activity.
The first randomized trial, Symplicity HTN-2,
assigned 106 patients with systolic blood
pressure [160 mmHg (or [150 mmHg in type
2 diabetics) despite C3 anti-hypertensive drugs
to RDT or to usual care [1]. RDT was performed
using the single point electrode Simplicity
catheter (Medtronic, MN, USA) advanced via
the femoral artery into the renal artery. Up to
six radiofrequency ablations (each for 2 min)
Fig. 1 Sympathetic nerves within and just beyond the
adventitia of the renal arteries [2]
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were applied at different longitudinal and
rotational positions to try to ensure maximum
nerve ablation. The primary end point, change
in office-based systolic blood pressure at
6 months, was significantly reduced in the
RDT group (32 systolic/12 diastolic mmHg;
P\0.0001) with no reduction in the control
group (1/0 mmHg; P not significant).
Ambulatory blood pressure drops of smaller
magnitude but consistent with office
measurements were noted. A durable effect
was reported at TCT October 2013 for patients
reaching 3-year follow-up (n = 40) with an
average blood pressure reduction of -33/-14
mmHg (P\0.01) from baseline and an overall
response rate (systolic blood pressure
drop C10 mmHg) in 85% of patients
randomized to RDT [2]. Regarding safety, one
procedural hematoma and one dissection
occurred but no late decline in renal function
or renal artery stenosis.
However, one limitation to the Simplicity
flex device was the time taken to complete the
required multiple ablation points. Several
second generation devices have been
developed with the aim of a faster, more
efficient procedure. The OneShot device
(Covidien, Dublin, Ireland) (Fig. 2) is a low-
pressure (\1 atm) balloon with a 360
continuous spiral electrode on the surface, 8
irrigation holes alongside the electrode to
reduce surrounding tissue damage (Fig. 2).
Ablation time is 2 min per artery. Twelve-
month results of the first in man study
showed an average blood pressure reduction of
31/10 mmHg [3]. The Vessix catheter (Boston
Scientific Corporation, Natick, MA, USA) is a
low-pressure balloon with two pairs of bipolar
low-wattage (1 W) surface electrodes providing
four ablation points in a helical arrangement
and an ablation time of 30 s per application
(Fig. 3). Interim 6-month results from 139 of
145 enrolled patients in the REDUCE-HTN trial
presented at TCT October, 2013 reported an
office blood pressure reduction of 24.6/
10.3 mmHg and ambulatory blood pressure
reduction of 11.2/6.3 mmHg [4]. The St Jude
EnligHTN catheter contains four electrodes
mounted on an expandable basket design
(Fig. 4). The second generation device has an
ablation time of 90 s per set of four
simultaneous ablations with two treatments
typically performed per artery. Early results of
this device in EnligHTN-III showed 26/9 mmHg
reduction of office blood pressure at 3 months
(n = 20) [5].
Fig. 2 OneShot renal denervation balloon catheter with
continuous spiral electrode and 8 irrigation holes [3]
Fig. 3 Vessix renal denervation balloon catheter with two
pairs of bipolar surface electrodes arranged in helical
fashion [4]
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Other recently CE-marked devices include
the Simplicity Spyral device (Medtronic) with
four electrodes arranged in a helical-shaped
nitinol catheter, the single-electrode Iberis
catheter (Terumo, Tokyo, Japan) designed for
use via radial access and a non-radiofrequency
device—the Paradise catheter (ReCor Medical,
Menlo Park, California, USA) comprising a
central transducer within a low-pressure
hydro-cooling balloon which emits ultrasound
energy in circumferential fashion. Additional
investigational technologies include the
irrigated five-electrode spiral ThermoCool
radiofrequency catheter (Cordis, NJ, USA),
multiple other developmental radiofrequency
devices, microinjection catheters for chemical
neurolysis such as the Peregrine catheter
(ablative solutions, Menlo Park, CA, USA) with
three micro-needles (250 micron) for
periadventitial injection of ethanol, and the
non-invasive, externally delivered, focused
ultrasound system from Kona Medical
(Bellevue, WA, USA).
In addition to consistent improvements in
blood pressure, patients with resistant
hypertension often have associated
comorbidities, some of which may benefit
from reduction of excessive sympathetic drive
achieved through RDT. Studies are currently
underway evaluating RDT in fields such as
congestive heart failure, atrial dysrhythmia,
and glycemic control in diabetes.
In summary, while varying approaches and
indications continue to be evaluated, 2013 in
many countries has seen renal denervation
move from being a largely research technique
into clinical service.
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Fig. 4 EnligHTN renal denervation system with four
electrodes mounted on an expandable basket catheter [5]
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